Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-15

Study Completion Date

2017-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780

Treatment of Venous Thromboembolism in Cancer Patients Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

COMPLETED

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

NCT05150938

Treatment of Venous Thromboembolism in Cancer Patients

COMPLETED

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban

NCT02746185

Neoplasm Venous Thromboembolism

COMPLETED PHASE3

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

NCT02555878

Neoplasms

COMPLETED PHASE3

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

NCT05112666

Treatment of Venous Thromboembolism in Cancer Patients

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer-associated thrombosis

Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type DRUG

15/20 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

15/20 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (≥18 years-of-age) with active cancer
* Patient with at least one index venous thromboembolism (VTE )
* ≥6-months of continuous eligibility prior to the index VTE event (baseline period).
* Newly initiated on rivaroxaban

Exclusion Criteria

* Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date
* Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No